Imo, the report is still tends towards the horrific, cash receipts for same period last year was $6.5 million compared to $4.3 million....
And I don't even want to delve too deeply into what the margins are possibly at now.
Still, there's something to build off. The thing that's closest is probably Alexiflam opportunity in Europe now that they're REACH compliant.
Ann: Appendix 4C - quarterly, page-28
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AJX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.62M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4238970 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 113120 | 1 |
View Market Depth
| Last trade - 16.12pm 25/07/2024 (20 minute delay) ? |
| AJX (ASX) Chart |
Day chart unavailable